See Hoe, Louise E. http://orcid.org/0000-0003-0553-205X
Wildi, Karin
Obonyo, Nchafatso G.
Bartnikowski, Nicole
McDonald, Charles
Sato, Kei
Heinsar, Silver
Engkilde-Pedersen, Sanne
Diab, Sara
Passmore, Margaret R.
Wells, Matthew A.
Boon, Ai-Ching
Esguerra, Arlanna
Platts, David G.
James, Lynnette
Bouquet, Mahe
Hyslop, Kieran
Shuker, Tristan
Ainola, Carmen
Colombo, Sebastiano M.
Wilson, Emily S.
Millar, Jonathan E.
Malfertheiner, Maximillian V.
Reid, Janice D.
O’Neill, Hollier
Livingstone, Samantha
Abbate, Gabriella
Sato, Noriko
He, Ting
von Bahr, Viktor
Rozencwajg, Sacha
Byrne, Liam
Pimenta, Leticia P.
Marshall, Lachlan
Nair, Lawrie
Tung, John-Paul
Chan, Jonathan
Haqqani, Haris
Molenaar, Peter
Li Bassi, Gianluigi
Suen, Jacky Y.
McGiffin, David C.
Fraser, John F.
Funding for this research was provided by:
national health and medical research council (GNT1145761)
prince charles hospital foundation (RF-04)
donald and joan wilson foundation
department of health, queensland (Bionics)
alfred foundation
centre for research excellence for advanced cardio-respiratory therapies improving organ support
griffith university
Article History
Received: 28 July 2021
Accepted: 23 November 2021
First Online: 24 December 2021
Declarations
:
: Sheep were used in this study. Animal studies were undertaken at the Queensland University of Technology (QUT) Medical Engineering Research Facility in Brisbane between March 2017 and December 2018. Animal ethics was approved by the QUT Animal Ethics Committee (AEC) (16000001109) and ratified by the University of Queensland AEC (QUT/393/17/QUT). All experiments were performed in accordance with the National Health and Medical Research Council (NHMRC) Australian Code of Practice for the Care and Use of Animals for Scientific Purposes 8th Edition 2013 and the Animal Care and Protection Act 2001 (QLD) and complied with the ARRIVE Guidelines.
: Not applicable.
: Outside of the submitted work, Professor Fraser receives reimbursement for travel costs and incidentals when presenting research he has performed in collaboration with Fisher and Paykel Healthcare. Professor Fraser is the co-founder and CEO of De Motu Cordis Pty Limited, and the Quantum Medical Innovation Fund. He is also the co-founder of BiVACOR™ Pty Ltd. In addition, Prof. Fraser and his research group work with Fisher and Paykel healthcare, Mallinckrodt Pharmaceuticals, CSL, BiVACOR™, De Motu Cordis Pty Limited, and Australian Red Cross Lifeblood. Professor McGiffin provides consultancy services to Abbott. Assoc Prof David Platts has acted as a clinical liaison with Philips Healthcare, GE Healthcare and Lantheus Medical Imaging. This has no direct impact on the contents of the manuscript. The other authors do not have any conflict of interest.